Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/11/2022 | Mkt Perform → Outperform | William Blair |
William Blair upgraded Novanta from Mkt Perform to Outperform
SC 13G/A - NOVANTA INC (0001076930) (Subject)
SC 13G - NOVANTA INC (0001076930) (Subject)
SC 13G/A - NOVANTA INC (0001076930) (Subject)
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m
Third Quarter 2024 GAAP Revenue of $244 million Third Quarter 2024 GAAP Net Income of $19 million Third Quarter 2024 GAAP Diluted Earnings Per Share of $0.53 Third Quarter 2024 Adjusted Earnings Per Share of $0.85 Third Quarter 2024 Adjusted EBITDA of $57 million Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the third quarter 2024. Financial Highlights Three Months Ended (In millions, except per share amounts) September 27, September 29, 2024 2023 GAAP
Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its third quarter 2024 results on Tuesday, November 5, 2024. The Company will host a conference call on Tuesday, November 5, 2024, at 10:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com. A replay of the audio webcast will be available approximately three hours after the conclusion of the cal
Second Quarter 2024 GAAP Revenue of $236 million Second Quarter 2024 GAAP Net Income of $13.8 million Second Quarter 2024 GAAP Diluted Earnings Per Share of $0.38 Second Quarter 2024 Adjusted Earnings Per Share of $0.73 Second Quarter 2024 Adjusted EBITDA of $51 million Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the second quarter 2024. Financial Highlights Three Months Ended (In millions, except per share amounts) June 28, June 30, 2024 2023 GAAP
3 - NOVANTA INC (0001076930) (Issuer)
3 - NOVANTA INC (0001076930) (Issuer)
4 - NOVANTA INC (0001076930) (Issuer)
Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that management will be participating at the CJS Securities 25th Annual New Ideas for the New Year Investor Conference on Tuesday, January 14, 2025, which is being held virtually. About Novanta Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary technology expertise and competencies in precision medicine and manufacturing, medical solutions, and robotics and automation with a proven ability to solve c
Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chair & Chief Executive Officer, and Robert Buckley, Chief Financial Officer, are scheduled to present at the J.P. Morgan 43rd Annual Healthcare Conference on Monday, January 13, 2025, in San Francisco, California. About Novanta Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary technology expertise and competencies in precision medicine and manufacturing, medical solutions, an
Third Quarter 2024 GAAP Revenue of $244 million Third Quarter 2024 GAAP Net Income of $19 million Third Quarter 2024 GAAP Diluted Earnings Per Share of $0.53 Third Quarter 2024 Adjusted Earnings Per Share of $0.85 Third Quarter 2024 Adjusted EBITDA of $57 million Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the third quarter 2024. Financial Highlights Three Months Ended (In millions, except per share amounts) September 27, September 29, 2024 2023 GAAP
10-Q - NOVANTA INC (0001076930) (Filer)
8-K - NOVANTA INC (0001076930) (Filer)
8-K - NOVANTA INC (0001076930) (Filer)